CUI Explorer

Controlled Substances

Information obtained by the Drug Enforcement Administration (DEA) or in DEA investigative reports related to controlled substances.

Registry statusNARA & DoD
MarkingSUB
Organizational index groupLaw Enforcement
Updated2026-05-15

This page exposes extracted CUI registry and authority analysis as crawlable text. The interactive explorer remains the operational workspace for filtering, comparison, and voice-agent aligned study.

Registry comparison

Field NARA Registry DoD Registry
Category description Information obtained by the Drug Enforcement Administration (DEA) or in DEA investigative reports related to controlled substances. Information obtained by the Drug Enforcement Administration (DEA) or in DEA investigative reports related to controlled substances.
Category marking SUB SUB
Banner marking CUI//SP-SUB No corresponding field
Basic or Specified Specified No corresponding field
Authorities 28 CFR 0.103 28 CFR 1.103
DoD applicable policies No corresponding field None listed
Required warning statement No corresponding field None listed
Required dissemination control CUI//SP-SUB, CU//SP-SUB None listed
Examples No corresponding field Investigative reports, Amount of drugs confiscated, Identity of officers involved
Registry date July 29, 2025 2026-05-15

Authority analysis

Authority title
Registry authority evidence compiled; primary authority text analysis pending
Authorities
Multiple registry authorities
Source currency
NARA last reviewed: July 29, 2025 | DoD detail accessed: 2026-05-15
How the authority operates
NARA registry status: Specified. Per-authority NARA status values: Specified. NARA banner marking evidence: CUI//SP-SUB, CU//SP-SUB. The registry evidence is preserved here; detailed primary-law or regulation text analysis remains pending for this category.

Trigger conditions

  • NARA category scope: Information obtained by the Drug Enforcement Administration (DEA) or in DEA investigative reports related to controlled substances.

Covered information

  • Investigative reports
  • Amount of drugs confiscated
  • Identity of officers involved
  • Registry-described information: Information obtained by the Drug Enforcement Administration (DEA) or in DEA investigative reports related to controlled substances.

Specified controls

Nara basic or specified
Specified
Nara authority rows
28 CFR 0.103 | status: Specified | banner: CU//SP-SUB
Nara banner markings
CUI//SP-SUB, CU//SP-SUB

Safeguarding and dissemination controls

NARA Registry
CUI//SP-SUB, CU//SP-SUB
DoD Registry
None listed
Authority analysis
No DoD required dissemination control is listed on the registry page. Apply approved limited dissemination controls only when required or permitted by the designating agency or governing authority.
Basic or Specified
Use the registry assertions, NARA authority rows, DoD authorities, DoD policies, warning statements, required dissemination controls, and examples first. Where the cited authority does not specify a handling detail, apply CUI Basic safeguards and dissemination rules so long as they do not conflict with the authority or agency-specific controls.

Related authorities

Authority-by-authority detail

28 CFR 0.103

Listed by: NARA Registry, Related authorities

Designation evidence

  • NARA authority row: 28 CFR 0.103 | status: Specified | banner: CU//SP-SUB.
  • Related authority evidence: 28 CFR 0.103 | status: Specified | banner: CU//SP-SUB

Extracted authority meaning

None listed

Operating conditions

  • NARA category scope used with this authority: Information obtained by the Drug Enforcement Administration (DEA) or in DEA investigative reports related to controlled substances.
  • 28 CFR 0.103 | status: Specified | banner: CU//SP-SUB
  • NARA registry status: Specified. Per-authority NARA status values: Specified. NARA banner marking evidence: CUI//SP-SUB, CU//SP-SUB. The registry evidence is preserved here; detailed primary-law or regulation text analysis remains pending for this category.
  • NARA category scope: Information obtained by the Drug Enforcement Administration (DEA) or in DEA investigative reports related to controlled substances.

Safeguarding and dissemination controls

  • NARA registry control evidence: status Specified; banner marking CU//SP-SUB.
  • Nara basic or specified: Specified
  • Nara authority rows: 28 CFR 0.103 | status: Specified | banner: CU//SP-SUB
  • Nara banner markings: CUI//SP-SUB, CU//SP-SUB
  • No DoD required dissemination control is listed on the registry page. Apply approved limited dissemination controls only when required or permitted by the designating agency or governing authority.
  • Use the registry assertions, NARA authority rows, DoD authorities, DoD policies, warning statements, required dissemination controls, and examples first. Where the cited authority does not specify a handling detail, apply CUI Basic safeguards and dissemination rules so long as they do not conflict with the authority or agency-specific controls.

28 CFR 1.103

Listed by: DoD Registry, Related authorities

Designation evidence

  • DoD authority row: 28 CFR 1.103. DoD lists this citation for the category; this DoD detail page does not display a separate Basic/Specified field.
  • Related authority evidence: DoD lists this authority for the category; the linked authority text is extracted below when available.
  • Registry designation context: Specified, CUI//SP-SUB. The linked authority text contains category-scope or applicability language that helps determine when the information falls within this CUI category. The linked authority text contains disclosure, access, protection, release, dissemination, or distribution-control language relevant to handling. The linked authority text contains violation, penalty, sanction, or enforcement language that may affect consequences for mishandling.
  • Registry designation for this category is Specified with banner CUI//SP-SUB.

Extracted authority meaning

  • Subpart R—Drug Enforcement
  • Registry designation context: Specified, CUI//SP-SUB. The linked authority text contains category-scope or applicability language that helps determine when the information falls within this CUI category. The linked authority text contains disclosure, access, protection, release, dissemination, or distribution-control language relevant to handling. The linked authority text contains violation, penalty, sanction, or enforcement language that may affect consequences for mishandling.

Operating conditions

  • DoD category scope used with this authority: Information obtained by the Drug Enforcement Administration (DEA) or in DEA investigative reports related to controlled substances.
  • DoD lists this authority for the category; the linked authority text is extracted below when available.
  • NARA registry status: Specified. Per-authority NARA status values: Specified. NARA banner marking evidence: CUI//SP-SUB, CU//SP-SUB. The registry evidence is preserved here; detailed primary-law or regulation text analysis remains pending for this category.
  • NARA category scope: Information obtained by the Drug Enforcement Administration (DEA) or in DEA investigative reports related to controlled substances.
  • Extracted authority condition: (a) The Administrator of DEA is au- thorized— (1) To release information obtained by DEA and DEA investigative reports to Federal, State, and local officials engaged in the enforcement of laws re- lated to controlled substances.
  • Extracted authority condition: For example, it does not inhibit the exchange of information between governmental officials concerning the use and abuse of controlled substances as provided for by section 503(a)(1) of the Controlled Substances Act (21 U.S.C. 873(a)(1)). [Order No. 520–73, 38 FR 18380, July 10, 1973, as amended by Order No. 2614–2002, 67 FR 58990, Sept. 19, 2002] § 0.103a Delegations respecting claims against the Drug Enforcement Ad- ministration.
  • Extracted authority condition: (2) To release information obtained by DEA and DEA investigative reports to Federal, State, and local prosecu- tors, and State licensing boards, en- gaged in the institution and prosecu- tion of cases before courts and licens- ing boards related to controlled sub- stances.
  • Extracted authority condition: All DEA Laboratory Directors are author- ized to release information pursuant to 28 CFR 0.103(a)(1) and (2) that is obtained by a DEA laboratory, and to authorize the testi- mony of DEA laboratory personnel in re- sponse to prosecution subpoenas or demands under 28 CFR 0.103(a)(3).

Safeguarding and dissemination controls

  • Nara basic or specified: Specified
  • Nara authority rows: 28 CFR 0.103 | status: Specified | banner: CU//SP-SUB
  • Nara banner markings: CUI//SP-SUB, CU//SP-SUB
  • No DoD required dissemination control is listed on the registry page. Apply approved limited dissemination controls only when required or permitted by the designating agency or governing authority.
  • Use the registry assertions, NARA authority rows, DoD authorities, DoD policies, warning statements, required dissemination controls, and examples first. Where the cited authority does not specify a handling detail, apply CUI Basic safeguards and dissemination rules so long as they do not conflict with the authority or agency-specific controls.
  • Extracted authority control: (c) The development and implemen- tation of a procedure to release prop- erty seized under section 511 of the Controlled Substances Act (21 U.S.C.
  • Extracted authority control: (a) The Administrator of DEA is au- thorized— (1) To release information obtained by DEA and DEA investigative reports to Federal, State, and local officials engaged in the enforcement of laws re- lated to controlled substances.
  • Extracted authority control: All DEA Special Agents-in-Charge are authorized to take cus- tody of, and make disposition of, controlled substances seized pursuant to 21 U.S.C. 824(g).
  • Extracted authority control: All DEA Laboratory Directors are author- ized to release information pursuant to 28 CFR 0.103(a)(1) and (2) that is obtained by a DEA laboratory, and to authorize the testi- mony of DEA laboratory personnel in re- sponse to prosecution subpoenas or demands under 28 CFR 0.103(a)(3).
  • Extracted authority control: (3) To authorize the testimony of DEA officials in response to subpoenas or demands issued by the prosecution in Federal, State, or local criminal cases involving controlled substances.
  • Extracted authority control: (a) All DEA criminal investigators (series 1811 under Of- fice of Personnel Management regulations) and special agents of the FBI are authorized to exercise all of the powers of enforcement personnel granted by 21 U.S.C. 876, 878, and 879; to serve subpoenas, administer oaths, ex- amine witnesses, and receive evidence under 21 U.S.C. 875; to execute administrative in- spection warrants under 21 U.S.C. 880; and to seize property under 21 U.S.C. 881 and 21 CFR 1316.71 et seq.

Authority excerpts

Extracted authority passage 2

(c) The development and implemen- tation of a procedure to release prop- erty seized under section 511 of the Controlled Substances Act (21 U.S.C.

Extracted authority passage 3

(a) The Administrator of DEA is au- thorized— (1) To release information obtained by DEA and DEA investigative reports to Federal, State, and local officials engaged in the enforcement of laws re- lated to controlled substances.

Extracted authority passage 4

All DEA Special Agents-in-Charge are authorized to take cus- tody of, and make disposition of, controlled substances seized pursuant to 21 U.S.C. 824(g).

Extracted authority passage 5

All DEA Laboratory Directors are author- ized to release information pursuant to 28 CFR 0.103(a)(1) and (2) that is obtained by a DEA laboratory, and to authorize the testi- mony of DEA laboratory personnel in re- sponse to prosecution subpoenas or demands under 28 CFR 0.103(a)(3).

Extracted authority passage 6

For example, it does not inhibit the exchange of information between governmental officials concerning the use and abuse of controlled substances as provided for by section 503(a)(1) of the Controlled Substances Act (21 U.S.C. 873(a)(1)). [Order No. 520–73, 38 FR 18380, July 10, 1973, as amended by Order No. 2614–2002, 67 FR 58990, Sept. 19, 2002] § 0.103a Delegations respecting claims against the Drug Enforcement Ad- ministration.